| Assessment Status | Awaiting full HTA submission from Applicant |
| HTA ID | 24004 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 02/02/2024 |
| Rapid review completed | 09/02/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/02/2024 |
| Pre-submission consultation with Applicant | 09/04/2024 |
